Remember back in the fall of 2011 when GE committed $1 billion to cancer research and development? A new video put out by the GE Global Research Center commemorating National Cancer Research Month gives a glimpse into some of the work the multidisciplinary research team is doing along several points in the continuum of care for cancer, from diagnosis to remission.
Much of the technology discussed is imaging-focused, but among other interesting developments is molecular pathology technology that would look at more than 60 disease markers in a patient’s tumor and help physicians gauge the aggressiveness of a tumor and what kind of treatments the patient might respond to.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
On the treatment side, researcher Reginald Smith says a team is developing new tools for the implementation of emerging targeted, cellular therapies in cancer. Last year, GE opened a new cell science lab in Wales and told Outsourcing-pharma.com that it was working on technologies for multiplying cells and determining the toxicity of drug candidates.
There’s one point noticeably missing from the GE’s “continuum of cancer treatment,” and that’s prevention. But over the past few years, the healthcare side of the company has been making a modest effort there with its annual #GetFit campaign. It’s a social media-driven public awareness campaign created to promote healthy habits that can reduce the likelihood of developing cancer.
[Screen cap and video from CE GRC]